Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer

NCT00601861 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description

Conditions

Cancer
Malignant Melanoma

Interventions

DRUG: recombinant interleukin-21

Sponsor

Novo Nordisk A/S